These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36107574)

  • 21. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
    J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-insulin-dependent Diabetes Mellitus Induced by Immune Checkpoint Inhibitor Therapy in an Insulinoma-associated Antigen-2 Autoantibody-positive Patient with Advanced Gastric Cancer.
    Ohara N; Kobayashi M; Ikeda Y; Hoshi T; Morita S; Kanefuji T; Yagi K; Suda T; Takada T; Hasegawa G; Sato Y; Hirano K; Kosugi SI
    Intern Med; 2020 Feb; 59(4):551-556. PubMed ID: 31708539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. End-of-life impact of concurrent diabetes mellitus and adrenal insufficiency as immune-related adverse events in an advanced non-small cell lung cancer patient.
    Nakamura T; Takeyasu Y; Yoshida T; Ohashi K; Ohe Y
    Thorac Cancer; 2022 Nov; 13(21):3073-3075. PubMed ID: 36195556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review.
    Fu S; Wang T; Xu F
    J Oncol Pharm Pract; 2021 Sep; 27(6):1548-1552. PubMed ID: 33435825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report.
    Kikuchi F; Saheki T; Imachi H; Kobayashi T; Fukunaga K; Ibata T; Sato S; Ban N; Lyu J; Japar S; Murao K
    J Med Case Rep; 2021 Apr; 15(1):214. PubMed ID: 33892782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
    de Filette JMK; Pen JJ; Decoster L; Vissers T; Bravenboer B; Van der Auwera BJ; Gorus FK; Roep BO; Aspeslagh S; Neyns B; Velkeniers B; Kharagjitsingh AV
    Eur J Endocrinol; 2019 Sep; 181(3):363-374. PubMed ID: 31330498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes.
    Kotwal A; Haddox C; Block M; Kudva YC
    BMJ Open Diabetes Res Care; 2019; 7(1):e000591. PubMed ID: 30899528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
    Ishi A; Tanaka I; Iwama S; Sakakibara T; Mastui T; Kobayashi T; Hase T; Morise M; Sato M; Arima H; Hashimoto N
    Endocr J; 2021 May; 68(5):613-620. PubMed ID: 33790087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
    Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
    J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
    Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New onset diabetes after nivolumab treatment.
    Capitao R; Bello C; Fonseca R; Saraiva C
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29378735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment.
    Hatayama S; Kodama S; Kawana Y; Otake S; Sato D; Horiuchi T; Takahashi K; Kaneko K; Imai J; Katagiri H
    J Diabetes Investig; 2022 Aug; 13(8):1458-1460. PubMed ID: 35396830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
    Zhang Z; Sharma R; Hamad L; Riebandt G; Attwood K
    Diabetes Res Clin Pract; 2023 Aug; 202():110776. PubMed ID: 37311494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab.
    Zand Irani A; Gibbons H; Teh WX
    BMJ Case Rep; 2023 Apr; 16(4):. PubMed ID: 37011994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
    Harsch IA; Konturek PC
    Wiad Lek; 2018; 71(5):945-948. PubMed ID: 30176620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral.
    Kusuki K; Suzuki S; Mizuno Y
    Endocrinol Diabetes Metab Case Rep; 2020 Apr; 2020():. PubMed ID: 32478673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetic ketoacidosis as a hallmark of autoimmune diabetes occurring after two cycles of cemiplimab.
    Jouneghani NS; Phillip J; Dasanu CA
    J Oncol Pharm Pract; 2022 Apr; 28(3):722-724. PubMed ID: 34791931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
    Hong AR; Yoon JH; Kim HK; Kang HC
    Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer.
    Ichihara S; Kunishige M; Kadota N; Okano Y; Machida H; Hatakeyama N; Naruse K; Shinohara T; Takeuchi E
    Thorac Cancer; 2023 Jan; 14(1):81-84. PubMed ID: 36411591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.